Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.41 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | GRM8 | O00222 | 1/20 | 0.41 |
| ▸ | GRM6 | O15303 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 1/20 | 0.39 |
| ▸ | GABRD | O14764 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL30548563 | 0.89 | TSHR (0.34) | TSHRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL2679966 | 0.87 | CYP2C19 (0.47) | TSHRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL13245968 | 0.83 | LMNA (0.33) | TSHRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL2203295 | 0.82 | LMNA (0.41) | TSHRCYP2C19LMNAMAPK1ALDH1A1 | |
| SCHEMBL29611910 | 0.80 | LMNA (0.37) | TSHRCYP2C19LMNAMAPK1ALDH1A1 | |
| SCHEMBL2150720 | 0.80 | LMNA (0.37) | TSHRCYP2C19LMNAMAPK1ALDH1A1 | |
| SCHEMBL19160292 | 0.80 | LMNA (0.37) | TSHRCYP2C19LMNAMAPK1ALDH1A1 | |
| SCHEMBL17041847 | 0.79 | GRM2 (0.36) | TSHRCYP2C19LMNAGRM2GRM3 | |
| SCHEMBL8014639 | 0.78 | LMNA (0.36) | TSHRCYP2C19LMNAMAPK1ALDH1A1 | |
| SCHEMBL594661 | 0.78 | ALDH1A1 (0.38) | TSHRCYP2C19LMNAMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | claimed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | claimed |
| CN-116916924-B | MALT1 modulators and uses thereof | 稀有生物科学股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| EP-4695237-A1 | NOVEL COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2026-02-18 | — | — | EP | disclosed |
| US-20260008775-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | CONVELO THERAPEUTICS, INC. | 2026-01-08 | — | — | US | disclosed |
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4594309-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | Genentech Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4269400-B1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE SA (PL) | 2025-07-09 | — | — | EP | disclosed |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025104230-A1 | BENZOXAZOLES AS MODULATORS OF IL-17A | SANOFI (FR) | 2025-05-22 | — | — | WO | disclosed |
| CN-120019049-A | Azole modulators of cholesterol biosynthesis and their use for promoting remyelination | 基因泰克公司 | 2025-05-16 | — | — | CN | disclosed |
| WO-2005108361-A1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005080317-A2 | THERAPEUTIC AMIDE DERIVATIVES | PFIZER JAPAN, INC. (JP) | 2005-09-01 | — | — | WO | disclosed |
| EP-0873309-B1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2002-12-18 | — | — | EP | disclosed |
| EP-0950047-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| EP-0873309-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998025901-A1 | INDOLIN-2-ONE DERIVATIVES, METHOD FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
| WO-1997015556-A1 | 3-SPIRO-INDOLIN-2-ONE DERIVATIVES AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | SANOFI (FR) | 1997-05-01 | — | — | WO | disclosed |
| EP-0372817-B1 | NOVEL HETEROCYCLIC PESTICIDAL COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1992-05-13 | — | — | EP | disclosed |
| EP-0372817-A1 | Novel heterocyclic pesticidal compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260008775-A1 | AZOLE MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION | MAG, NR1H3, NR1H2 | TSHR 3152/4885CYP2C19 4504/4885LMNA 701/4885 |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | IL17A, IL2, IL36G | TSHR 3133/4885CYP2C19 867/4885LMNA 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.